Serum KLF5 and CXCL12 levels in patients with chronic obstructive pulmonary disease complicated with type II respiratory failure
Serum KLF5 and CXCL12 levels in COPD with II-RF
Abstract
[Objective] To explore the changes in the serum levels and significance of Kruppel-like factor 5 (KLF5) and chemokine ligand 12 (CXCL12) in individuals suffering from type II respiratory failure (II-RF) in conjunction with an acute exacerbation of chronic obstructive pulmonary disease (AECOPD).
[Methods] The observation group consisted of 164 patients with AECOPD and II-RF who were admitted to the hospital between January 2022 and January 2025. There were two groups of patients in the observation group: one with a good prognosis and another with a bad prognosis. The control group consisted of an additional 90 healthy people who were examined physically in the hospital throughout that time. The levels of serum KLF5 and CXCL12 in all research subjects were determined via enzyme-linked immunosorbent assay (ELISA). The associations between the blood levels of KLF5 and CXCL12 in patients with AECOPD combined with II-RF and the associated lung function indicators and the Acute Physiology and Chronic Health Evaluation II (APACHE II) score were examined using Pearson correlation analysis. The predictive value of serum KLF5 and CXCL12 for the prognosis of patients with AECOPD combined with II-RF was analyzed.
[Results] Serum KLF5 and CXCL12 levels were substantially higher in the observation group than in the control group (P<0.05). Compared with those in the group with a good prognosis, the levels of serum KLF5 and CXCL12, partial pressure of carbon dioxide (PCO2), and APACHE II score in the poor prognosis group were increased (P<0.05), both the arterial partial pressure of oxygen (PO2) and the forced expiratory volume in one second (FEV1), volume in one/forced vital capacity (FEV1/FVC%), and the percentage of the FEV1%PR to the expected value dropped (P<0.05). FEV1, FEV1/FVC, FEV1%Pred, and PO2 had a negative correlation (P<0.05) with serum KLF5 and CXCL12 levels, whereas PCO2 and the APACHE II score were positively correlated with the levels of serum KLF5 and CXCL12 (P<0.05). The results of the ROC curve analysis revealed that the area under the curve (AUC) for the combined detection of serum KLF5 and CXCL12 for predicting poor prognosis in patients with AECOPD combined with II-RF was 0.947 (95% CI: 0.913–0.981), which was significantly greater than the AUC predicted by the individual detection of KLF5 and CXCL12 [0.870 (95% CI: 0.816–0 923), 0.843 (95% CI: 0.770–0.915)], and the differences were statistically significant (Z = 2.413, P = 0.016; Z = 2.554, P = 0.011).
[Conclusion] The levels of serum KLF5 and CXCL12 in patients with AECOPD combined with II-RF were significantly increased. Additionally, detecting both of these indications together offers a good prognostic value for the poor prognosis of patients with II-RF and AECOPD. Therefore, serum KLF5 and CXCL12 can be used as serum markers for predicting the poor prognosis of patients with AECOPD combined with II-RF. Guide clinical diagnosis and treatment.
References
2.Tan D, Wang B, Cao P, Wang Y, Sun J, Geng P, Walline JH, Wang Y, Wang C. High flow nasal cannula oxygen therapy versus noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease with acute-moderate hypercapnic respiratory failure: a randomized controlled noninferiority trial. Crit Care. 2024 Jul 18;28(1):250. doi: 10.1186/s13054-024-05040-9. PMID: 39026242; PMCID: PMC11264824.
3.Bemand TJ, Chatoor R, Natale P, Strippoli G, Delaney A. Acetazolamide for metabolic alkalosis complicating respiratory failure with chronic obstructive pulmonary disease or obesity hypoventilation syndrome: a systematic review. Thorax. 2023 Oct;78(10):1004-1010. doi: 10.1136/thorax-2023-219988. Epub 2023 May 22. PMID: 37217290.
4.Chen Y, Sang J, Fu L, Zhang Y. Knowledge Domain and Emerging Trends in the Treatment of Patients with Chronic Obstructive Pulmonary Disease Combined with Respiratory Failure: A Scientometric Review Based on CiteSpace Analysis. COPD. 2025 Dec;22(1):2441184. doi: 10.1080/15412555.2024.2441184. Epub 2025 Feb 27. PMID: 40017029.
5.Ketan PS, Kumar R, Aj M, Ish P, Chakrabarti S, Gupta NK, Gupta N. Postextubation high-flow nasal cannula oxygen therapy versus noninvasive ventilation in chronic obstructive pulmonary disease with hypercapnic respiratory failure. Monaldi Arch Chest Dis. 2023 Jul 28;94(2). doi: 10.4081/monaldi.2023.2576. PMID: 37522869.
6.Hawkins NM, Peterson S, Salimian S, Demers C, Keshavjee K, Virani SA, Mancini GBJ, Wong ST. Epidemiology and treatment of heart failure with chronic obstructive pulmonary disease in Canadian primary care. ESC Heart Fail. 2023 Dec;10(6):3612-3621. doi: 10.1002/ehf2.14497. Epub 2023 Oct 3. PMID: 37786365; PMCID: PMC10682874.
7.Bertoletti L, Couturaud F, Sanchez O, Jimenez D. Pulmonary Embolism and Chronic Obstructive Pulmonary Disease. Semin Thromb Hemost. 2023 Nov;49(8):809-815. doi: 10.1055/s-0042-1756190. Epub 2022 Sep 15. PMID: 36108648.
8.Figueira-Gonçalves JM, García-Bello MÁ, Ramallo-Fariña Y, Méndez R, Latorre Campos A, González-Jiménez P, Peces-Barba G, Molina-Molina M, España PP, García E, Domínguez-Pazos SJ, García Clemente M, Panadero C, de la Rosa-Carrillo D, Sibila O, Martínez-Pitarch MD, Toledo-Pons N, López-Ramirez C, Almonte-Batista W, Macías-Paredes A, Badenes-Bonet D, Pérez-Rodas EN, Lázaro J, Quirós Fernández S, Cordovilla R, Cano-Pumarega I, Torres A, Menendez R; RECOVID. Persistent Respiratory Failure and Re-Admission in Patients with Chronic Obstructive Pulmonary Disease Following Hospitalization for COVID-19. Int J Chron Obstruct Pulmon Dis. 2023 Nov 7;18:2473-2481. doi: 10.2147/COPD.S428316. PMID: 37955022; PMCID: PMC10638925.
9.Zhu Y, Zhen W, Zhang X, Shi Z, Zhang L, Zhou J, Meng X. Extracorporeal Carbon Dioxide Removal in Patients with Acute Respiratory Distress Syndrome or Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis. Blood Purif. 2023;52(2):103-113. doi: 10.1159/000525983. Epub 2022 Aug 29. PMID: 36037805.
10.Zhou Z, Wang Y, Wang Y, Yang B, Xu C, Wang S, Yang W. A Diagnostic Nomogram for Predicting Hypercapnic Respiratory Failure in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis. 2024 May 18;19:1079-1091. doi: 10.2147/COPD.S454558. PMID: 38783895; PMCID: PMC11112130.
11.Wu L, Zheng Y, Liu J, Luo R, Wu D, Xu P, Wu D, Li X. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19. Aging (Albany NY). 2021 Apr 20;13(8):10833-10852. doi: 10.18632/aging.202860. Epub 2021 Apr 20. PMID: 33879634; PMCID: PMC8109137.
12.Singh R, Yumnam BD, Rajawat GS, Sharma A. Role of Heart Rate, Acidosis, Consciousness, Oxygenation, and Respiratory Rate Score in Predicting Outcomes of Noninvasive Ventilation in Chronic Obstructive Pulmonary Disease Patients. J Assoc Physicians India. 2024 Oct;72(10):50-52. doi: 10.59556/japi.72.0666. PMID: 39390859.
13.Shi Q, Xu J, Zeng L, Lu Z, Chen Y. A nomogram for predicting short-term mortality in ICU patients with coexisting chronic obstructive pulmonary disease and congestive heart failure. Respir Med. 2024 Nov-Dec;234:107803. doi: 10.1016/j.rmed.2024.107803. Epub 2024 Sep 7. PMID: 39251097.
14.Wu L, Zhong Y, Wu D, Xu P, Ruan X, Yan J, Liu J, Li X. Immunomodulatory Factor TIM3 of Cytolytic Active Genes Affected the Survival and Prognosis of Lung Adenocarcinoma Patients by Multi-Omics Analysis. Biomedicines. 2022 Sep 10;10(9):2248. doi: 10.3390/biomedicines10092248. PMID: 36140350; PMCID: PMC9496572.
15.Nath S, Qurashi H, Kitsios GD, Bain W, Aneis H, Suber T, Prendergast N, Hensley M, Schaefer C, Zhang Y, Bon J, McVerry BJ, Evankovich J, Shah FA. Clinical and biologic profiles of patients with acute respiratory distress syndrome by prevalence of chronic obstructive pulmonary disease or emphysema; a cohort study. Respir Res. 2024 Nov 8;25(1):400. doi: 10.1186/s12931-024-03027-2. PMID: 39516808; PMCID: PMC11549746.
16.Akbaş T, Güneş H. Characteristics and outcomes of patients with chronic obstructive pulmonary disease admitted to the intensive care unit due to acute hypercapnic respiratory failure. Acute Crit Care. 2023 Feb;38(1):49-56. doi: 10.4266/acc.2022.01011. Epub 2023 Feb 27. PMID: 36935534; PMCID: PMC10030250.
17.Purohit S, Madan M, Kumar R, Kaushik R, Ish P, Aj M, Chakrabarti S, Gupta NK, Gupta N. Comparison of immediate withdrawal and stepwise reduction in duration of noninvasive ventilation in chronic obstructive pulmonary disease patients presenting with acute hypercapnic respiratory failure. Monaldi Arch Chest Dis. 2023 Oct 12;94(3). doi: 10.4081/monaldi.2023.2755. PMID: 37823836.
18.Wu L, Liu Q, Ruan X, Luan X, Zhong Y, Liu J, Yan J, Li X. Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD). Biomedicines. 2023 Jun 29;11(7):1861. doi: 10.3390/biomedicines11071861. PMID: 37509501; PMCID: PMC10377220.
19.Chen X, Dai L, Ma JZ, Chu XX, Dai L, Liu JM, Guo SW, Ru XW, Zhuang XS. Clinical study of NFNC in the treatment of acute exacerbation chronic obstructive pulmonary disease patients with respiratory failure. World J Clin Cases. 2023 Nov 16;11(32):7770-7777. doi: 10.12998/wjcc.v11.i32.7770. PMID: 38073695; PMCID: PMC10698426.
20.Gao P, Chen L, He L, Lei J, Luo M, Gu L. Respiratory virus infections and adenovirus characteristics during acute exacerbation of chronic obstructive pulmonary disease. Technol Health Care. 2024;32(6):4203-4221. doi: 10.3233/THC-240010. PMID: 39058463; PMCID: PMC11613029.
21.Liu A, Zhou Y, Pu Z. Effects of high-flow nasal cannula oxygen therapy for patients with acute exacerbation of chronic obstructive pulmonary disease in combination with type II respiratory failure. J Int Med Res. 2023 Jun;51(6):3000605231182558. doi: 10.1177/03000605231182558. PMID: 37377101; PMCID: PMC10328027.
22.He J, Luo W, Mei Y, Xu Y, Ding S. Nalmefene combined noninvasive positive-pressure ventilation in Chinese patients with chronic obstructive pulmonary disease coupled with type II respiratory failure: A meta-analysis. Medicine (Baltimore). 2023 Aug 4;102(31):e34624. doi: 10.1097/MD.0000000000034624. PMID: 37543782; PMCID: PMC10403022.
23.Wu L, Zheng Y, Ruan X, Wu D, Xu P, Liu J, Wu D, Li X. Long-chain noncoding ribonucleic acids affect the survival and prognosis of patients with esophageal adenocarcinoma through the autophagy pathway: construction of a prognostic model. Anticancer Drugs. 2022 Jan 1;33(1):e590-e603. doi: 10.1097/CAD.0000000000001189. PMID: 34338240; PMCID: PMC8670349.
24.Kaur S, Larsen E, Harper J, Purandare B, Uluer A, Hasdianda MA, Umale NA, Killeen J, Castillo E, Jariwala S. Development and Validation of a Respiratory-Responsive Vocal Biomarker-Based Tool for Generalizable Detection of Respiratory Impairment: Independent Case‒Control Studies in Multiple Respiratory Conditions Including Asthma, Chronic Obstructive Pulmonary Disease, and COVID-19. J Med internet Res. 2023 Apr 14;25:e44410. doi: 10.2196/44410. PMID: 36881540; PMCID: PMC10131712.
25.Chen ZZ, Yang CY, He Y, Yang K, Wang ZP. Psychological nursing effect on chronic obstructive pulmonary disease patients with respiratory failure. Medicine (Baltimore). 2025 Jul 25;104(30):e43515. doi: 10.1097/MD.0000000000043515. PMID: 40725961; PMCID: PMC12303450.
26.Wu L, Zhong Y, Yu X, Wu D, Xu P, Lv L, Ruan X, Liu Q, Feng Y, Liu J, Li X. Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research. Anticancer Drugs. 2022 Oct 1;33(9):943-959. doi: 10.1097/CAD.0000000000001319. Epub 2022 Aug 9. PMID: 35946526; PMCID: PMC9481295.
27.Zhang Y, Chen H, Hu S, Chen C, Chen W. Construction and validation of a nomogram prediction model for death risk in patients with chronic obstructive pulmonary disease complicated by hypercapnic respiratory failure in the intensive care unit. Respir Med. 2025 Aug-Sep;245:108188. doi: 10.1016/j.rmed.2025.108188. Epub 2025 Jun 1. PMID: 40460897.
28.Xiao J, Wu Y, Wang L, Zhou H. Effect of Precise Pulmonary Rehabilitation Nursing Intervention Combined With Simultaneous Inhalation Therapy and Noninvasive Ventilation for Chronic Obstructive Pulmonary Disease Patients With Chronic Hypercapnic Respiratory Failure. Clin Respir J. 2025 Feb;19(2):e70049. doi: 10.1111/crj.70049. PMID: 39909832; PMCID: PMC11798664.
29.Wu L, Li H, Liu Y, Fan Z, Xu J, Li N, Qian X, Lin Z, Li X, Yan J. Research progress of 3D-bioprinted functional pancreas and in vitro tumor models. International Journal of Bioprinting. 2024, 10(1), 1256. doi: 10.36922/ijb.1256.
30.Xie S, Li X, Liu Y, Huang J, Yang F. Effect of home noninvasive positive pressure ventilation combined with pulmonary rehabilitation on dyspnea severity and quality of life in patients with severe stable chronic obstructive pulmonary disease combined with chronic type II respiratory failure: a randomized controlled trial. BMC Pulm Med. 2025 Apr 21;25(1):185. doi: 10.1186/s12890-025-03656-3. PMID: 40259286; PMCID: PMC12013138.Wu L, Li X, Qian X, Wang S, Liu J, Yan J. Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity. Vaccines (Basel). 2024 Feb 12;12(2):186. doi: 10.3390/vaccines12020186. PMID: 38400169; PMCID: PMC10891594.
31.Carrera-Salinas A, González-Díaz A, Ehrlich RL, Berbel D, Tubau F, Pomares X, Garmendia J, Domínguez MÁ, Ardanuy C, Huertas D, Marín A, Montón C, Mell JC, Santos S, Marti S. Genetic Adaptation and Acquisition of Macrolide Resistance in Haemophilus spp. during Persistent Respiratory Tract Colonization in Chronic Obstructive Pulmonary Disease (COPD) Patients Receiving Long-Term Azithromycin Treatment. Microbiol Spectr. 2023 Feb 14;11(1):e0386022. doi: 10.1128/spectrum.03860-22. Epub 2022 Dec 8. PMID: 36475849; PMCID: PMC9927455.
32.Wu L, Chen X, Zeng Q, Lai Z, Fan Z, Ruan X, Li X, Yan J. NR5A2 gene affects the overall survival of LUAD patients by regulating the activity of CSCs through SNP pathway by OCLR algorithm and immune score. Heliyon. 2024 Mar 28;10(7):e28282. doi: 10.1016/j.heliyon.2024.e28282. PMID: 38601554; PMCID: PMC11004709.
33.Zhou R, Pan D. Association between admission heart rate and in-hospital mortality in patients with acute exacerbation of chronic obstructive pulmonary disease and respiratory failure: a retrospective cohort study. BMC Pulm Med. 2024 Mar 5;24(1):111. doi: 10.1186/s12890-024-02934-w. PMID: 38443791; PMCID: PMC10913584.
34.Spiesshoefer J, Herkenrath SD, Treml M, Pietzke-Calcagnile A, Hagmeyer L, Regmi B, Matthes S, Young P, Boentert M, Randerath WJ. Inspiratory Muscle Dysfunction Mediates and Predicts a Disease Continuum of Hypercapnic Failure in Chronic Obstructive Pulmonary Disease. Respiration. 2024;103(4):182-192. doi: 10.1159/000536589. Epub 2024 Feb 7. PMID: 38325348.
Copyright (c) 2026 Fangfang Liu, Na Wang, Ruru Sun, Songmin Fu, Yi Chen, Pingping Dong
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.